Information Related to Novel Coronavirus
Posted on April 17, 2020
Updated on May 16, 2023
We wish to offer our sympathies to everyone around the world affected by the novel coronavirus infection, their families, and others such as healthcare workers and first responders involved. We also extend our deepest condolences to those who have lost loved ones.
Chugai’s mission is to dedicate itself to adding value by creating and delivering innovative products and services for the medical community and human health around the world. We are committed to ensuring the health and safety of our stakeholders and employees, and ensuring the stable supply of our drugs to patients.
Chugai Group Efforts
Stable supply of our drugs
We have taken the necessary measures to supply our drugs inside and outside of Japan, and no adverse impact is seen at this time. Going forward, we will take steps to ensure a continued stable supply, even if the infection is prolonged or becomes more serious.
Measures to prevent the spread of the coronavirus in Japan
Since March 2020, in line with the policies of the government and local governments and the resurgence of infections, we have issued “COVID-19 Response Policy” as necessary, including recommendations for attendance at work, meetings and business trips, holding of events, and reporting and behavioral standards in the event of an illness. In line with the change in the classification of infectious diseases on May 8, 2023, we have ended the distribution of our response policy. On and after May 8, we will shift to a “new way of working after COVID-19” that puts more emphasis on face-to-face communication. In addition, we will implement infection prevention measures based on the characteristics of each worksite and individual voluntary decisions, as well as implementing behavioral standards in the event of an infection.
Situation at Chugai Group companies outside of Japan
At this time, there is no impact on corporate activities at any Chugai Group company.
Chugai Group Support Activities
Chugai Activities
- Chugai has made a financial donation of RMB 1 million to the Red Cross Society of China to support activities to control the coronavirus outbreak in the People’s Republic of China. (Mar 5, 2020)
- Fuji Gotemba Research Laboratories has donated medical supplies (including 600 protective raincoats) to Gotemba City. (May 8, 2020)
- Chugai has donated JPY 50 million to The Nippon Foundation and the Tokyo Metropolitan Government to support the efforts of healthcare professionals in Japan who are engaged in the treatment and prevention of coronavirus (COVID-19). (June 10, 2020)
- In order to help prevent the spread of COVID-19 infection, Chugai has donated five million yen to the Kanagawa Corona Medical and Welfare Support Fund to support people working in medical, welfare, and nursing care facilities and those who support them. (July 20, 2020)
Group Company Activities
- Chugai Pharmabody Research (CPR) has made a donation of S$12,000 to the Courage Fund of the Community Chest in Singapore to support the government’s efforts to combat the novel coronavirus. (Feb 18, 2020)
- Chugai Group companies in Europe have contributed a total of €120,000 to support medical professionals and those affected by the novel coronavirus pandemic. (May 22, 2020)
- UK: Chugai Pharma Europe and Chugai Pharma UK donated €40,000 to The National Emergencies Trust.
- France: Chugai Pharma France donated €40,000 to Fondation de France.
- Germany: Chugai Pharma Germany donated €40,000 to The German Red Cross.
Press Releases Related to Coronavirus
Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
